MLLT1

Protein ENL

7,486 patent compounds predicted against MLLT1, 4,081 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL215564	0.56	18/20
SCHEMBL214952	0.54	17/20
SCHEMBL216157	0.57	11/20
SCHEMBL1391130	0.44	7/20
SCHEMBL1251076	0.51	6/20
Hydrochloric Acid (SCHEMBL658509)	0.48	6/20
SCHEMBL489216	0.47	6/20
SCHEMBL489217	0.47	6/20
SCHEMBL72387	0.63	5/20
SCHEMBL1474945	0.60	5/20
SCHEMBL68613	0.51	5/20
SCHEMBL3466430	0.48	5/20
SCHEMBL1405586	0.46	5/20
SCHEMBL489494	0.44	5/20
SCHEMBL489495	0.44	5/20
SCHEMBL1665058	0.42	5/20
SCHEMBL1476381	0.57	4/20
SCHEMBL2925591	0.51	4/20
SCHEMBL1251668	0.47	4/20
SCHEMBL2538823	0.43	4/20

Germline variants in MLLT1 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full MLLT1 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to MLLT1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Treatment of Acute Lymphoblastic Leukemia in Children	PHASE3	COMPLETED
Role of the Therapy Tailored to Risk Factors in Treating Adult Patients (≤60) With Acute Myeloid Leukemia	PHASE3	UNKNOWN
A Prospective Multicenter Clinical Trial of MRD-based Treatment Strategy in Children and Young Adults With AML	PHASE3	UNKNOWN
CHIP-AML22/Master: An Open Label Complex Clinical Trial in Newly Diagnosed Pediatric de Novo AML Patients	PHASE3	RECRUITING
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation	PHASE1/PHASE2	RECRUITING
Induction Intensification in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia	PHASE2	COMPLETED
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
A Study of Revumenib and Mezigdomide in People With Leukemia	PHASE1/PHASE2	RECRUITING
Cord Blood Transplant in Adults With Blood Cancers	PHASE2	RECRUITING
Laromustine, Daunorubicin, and Cytarabine in Treating Patients With Acute Myeloid Leukemia	PHASE1/PHASE2	COMPLETED
A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia	PHASE2	RECRUITING
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene	PHASE1	COMPLETED
A Phase 1 Study of BMF-500 in Adults With Acute Leukemia	PHASE1	ACTIVE_NOT_RECRUITING
A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving	PHASE1	COMPLETED
A Clinical Study of HMPL-506 in Patients With Hematological Malignancies	PHASE1	RECRUITING
BY002 IIT Study in R/R Acute Leukemia	PHASE1	RECRUITING
Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome	PHASE1	COMPLETED
Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA.	nan	RECRUITING
Biomarkers in Samples of Bone Marrow From Patients With Acute Myeloid Leukemia	nan	COMPLETED
Better Leukemia Diagnostics Through AI (BELUGA)	nan	RECRUITING
Role of Biomarkers in Disease Progression in Samples From Patients With Acute Myeloid Leukemia	nan	COMPLETED
Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients	nan	COMPLETED
Functional Pharmacogenomics of Childhood Acute Lymphoblastic Leukemia in Taiwan	nan	UNKNOWN
Triple Negative Adult B-cell Acute Lymphoblastic Leukemia - TRINEG-ALL	nan	RECRUITING
Expression of TET1 Gene in Acute Leukaemia	nan	UNKNOWN
Long Non-coding RNAs and Their Role on Epigenome as Diagnostic Markers in Childhood Acute Lymphoblastic Leukemia of T Cells.	nan	UNKNOWN
Clinical and Genomic Registry of MDS in Asia	nan	UNKNOWN
Leukemia Stem Cell-based Assay to Predict Relapse and Survival in Patients With Acute Myeloid Leukemia	nan	RECRUITING
Study of Non-Myeloablative Haplo-identical Haematopoietic Stem Cell Transplantation in Patients With Haematological Malignancies or Acquired Aplastic Anaemia	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a MLLT1 binder may also engage these)

Protein	Name	Similarity
A2AM29	—	0.994	A2AM29 →
MLLT3	Protein AF-9	0.993	landscape →
Q80TZ9	—	0.992	Q80TZ9 →
Q92539	—	0.992	Q92539 →
A6QP06	—	0.992	A6QP06 →
Q90YL3	—	0.991	Q90YL3 →
P97868	—	0.991	P97868 →
Q24595	—	0.991	Q24595 →
Q99PI5	—	0.991	Q99PI5 →
BPTF	Nucleosome-remodeling factor subunit BPTF	0.991	landscape →
Q14AX6	—	0.991	Q14AX6 →
A0JMK9	—	0.990	A0JMK9 →
P48193	—	0.990	P48193 →
Q9BQK8	—	0.990	Q9BQK8 →
Q9H329	—	0.990	Q9H329 →
Q76LL6	—	0.990	Q76LL6 →
Q3MJK5	—	0.990	Q3MJK5 →
Q62901	—	0.990	Q62901 →
Q5TKR9	—	0.990	Q5TKR9 →
P61406	—	0.989	P61406 →
Q9P2R6	—	0.989	Q9P2R6 →
Q9Y2H5	—	0.989	Q9Y2H5 →
F1QIC4	—	0.989	F1QIC4 →
O75167	—	0.989	O75167 →
Q5RAK6	—	0.989	Q5RAK6 →
BRPF3	Bromodomain and PHD finger-containing protein 3	0.989	landscape →
Q8BG95	—	0.989	Q8BG95 →
Q8WML3	—	0.989	Q8WML3 →
B1AZP2	—	0.989	B1AZP2 →
D4AEC2	—	0.989	D4AEC2 →